By Fineline Cube Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has entered into a strategic collaboration with Sandoz (SWX: SDZ), covering up to 10 proposed monoclonal antibody (mAb) and/or antibody‑drug conjugate (ADC) biosimilar products or components developed by Henlius. The parties have also signed collaboration terms for an initial three agreed products and an option for one additional asset, further deepening the existing oncology biosimilars collaboration between the two companies.
Deal Structure
| Item | Detail |
|---|---|
| Parties | Shanghai Henlius Biotech (HKG: 2696) and Sandoz (SWX: SDZ) |
| Scope | Up to 10 proposed mAb and/or ADC biosimilar products or components |
| Initial Products | Three agreed assets, plus an option on one additional asset |
| Rights Granted | Exclusive registration and commercialization rights outside China, up to worldwide |
| Collaboration Model | Multi‑product portfolio framework spanning development, regulatory submissions, manufacturing, launch, commercialization, and lifecycle management |
| Prior Relationship | April 2025 exclusive commercialization partnership for HLX13 (ipilimumab biosimilar) across 46 countries and regions, including Europe and the US |
Initial Assets & Territories
| Asset | Proposed Biosimilar Of | Exclusive Territory |
|---|---|---|
| HLX05‑N | Cetuximab | US, Canada, EU and certain other European countries including UK and Switzerland, Japan, Australia and New Zealand; semi‑exclusive rights in certain Asian countries/regions and other markets |
| HLX16 | Evolocumab | All markets worldwide outside China |
| Belimumab biosimilar | Belimumab | All markets worldwide outside China |
Most of the partnered products are currently at early stages of development, and the two parties will collaborate closely from the earliest stages of project development.
Financial Terms
| Component | Value (USD) |
|---|---|
| Upfront Payment | Up to 77 million |
| Development Milestones & Development Budget Milestones | Up to 160 million |
| Sales Milestones | Up to 77 million |
| Total for Initial Three Products | Up to 314 million |
| Royalties | Tiered royalties on net sales |
| Option Fee (HLXTE‑HAase1001) | Non‑refundable 8 million |
In addition, Sandoz has obtained an option for HLXTE‑HAase1001, a recombinant human hyaluronidase, for a non‑refundable option fee of USD 8 million. If Sandoz exercises the option, the parties will enter into separate definitive agreements covering that product.
Market Impact & Outlook
- Platform Validation: A multi‑asset deal of this scale with Sandoz, a global leader in generics and biosimilars, validates Henlius’ biosimilar development and manufacturing platform and its ability to originate internationally competitive portfolios.
- Global Commercial Leverage: Granting Sandoz exclusive rights outside China — in several cases worldwide — gives the partnered assets access to an established global commercialization infrastructure, accelerating international market penetration.
- Portfolio Breadth: The framework spans oncology (cetuximab biosimilar), cardiometabolic disease (evolocumab biosimilar), and autoimmune disease (belimumab biosimilar), diversifying Henlius’ exposure across major therapeutic areas.
- Deepening Partnership: Building on the April 2025 HLX13 agreement covering 46 countries and regions, this expanded collaboration entrenches the Henlius–Sandoz relationship as one of the most significant China‑origin biosimilar partnerships with a multinational commercial partner.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding deal completion, product development, regulatory submissions, and commercial expectations for the partnered biosimilar assets. Actual results may differ due to risks including development outcomes, regulatory decisions, and competitive dynamics in the global biosimilars market.-Fineline Info & Tech